Skip to main content

Staphylococcal Infection

6
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Destiny Pharma
Destiny PharmaUK - Brighton
1 program
1
MupirocinPhase 41 trial
Active Trials
NCT02284555Completed12Est. Nov 2014
MSD
MSDIreland - Ballydine
2 programs
1
1
Daptomycin 4 mg/kgPhase 3
V710Phase 1
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
1
Daptomycin 4 mg/kgPhase 31 trial
V710Phase 11 trial
Active Trials
NCT00735839Completed40Est. Jun 2008
NCT00770341Completed122Est. Feb 2010
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
1
Mupirocin calciumPhase 21 trial
CephalexinPHASE_2_31 trial
Active Trials
NCT00729937Completed2,265Est. Jun 2013
NCT01827358Completed155Est. Jun 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Destiny PharmaMupirocin
Sharp TherapeuticsDaptomycin 4 mg/kg
Allergy TherapeuticsCephalexin
Allergy TherapeuticsMupirocin calcium
Sharp TherapeuticsV710

Clinical Trials (5)

Total enrollment: 2,594 patients across 5 trials

NCT02284555Destiny PharmaMupirocin

Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)

Start: Aug 2014Est. completion: Nov 201412 patients
Phase 4Completed
NCT00770341Sharp TherapeuticsDaptomycin 4 mg/kg

A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)

Start: Sep 2008Est. completion: Feb 2010122 patients
Phase 3Completed
NCT00729937Allergy TherapeuticsCephalexin

Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"

Start: Apr 2009Est. completion: Jun 20132,265 patients
Phase 2/3Completed
NCT01827358Allergy TherapeuticsMupirocin calcium

Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants

Start: Apr 2014Est. completion: Jun 2016155 patients
Phase 2Completed
NCT00735839Sharp TherapeuticsV710

V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)

Start: Mar 2008Est. completion: Jun 200840 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.